Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
28
TECX Quote, Financials, Valuation and Earnings
Last price:
$51.22
Seasonality move
:
-11.94%
Day range:
$48.02 - $53.41
52-week range:
$12.12 - $53.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.96x
Volume:
87.3K
Avg. volume:
102.8K
1-year change:
212.1%
Market cap:
$745.9M
Revenue:
--
EPS (TTM):
-$3.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic
|
-- | -- | -- | -50.01% | $74.67 |
|
ADVM
Adverum Biotechnologies
|
$62.5K | -$1.30 | -97.98% | -43.36% | $30.00 |
|
CAPR
Capricor Therapeutics
|
$3.6M | -$0.34 | -18.35% | -35% | -- |
|
EYPT
EyePoint Pharmaceuticals
|
$10.4M | -$0.54 | -25.19% | -53.26% | $33.45 |
|
RGNX
Regenxbio
|
$24.4M | -$1.10 | 5.56% | -21.21% | $37.64 |
|
SAVA
Cassava Sciences
|
-- | -$0.88 | -- | -28% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic
|
$50.56 | $74.67 | $745.9M | -- | $0.00 | 0% | -- |
|
ADVM
Adverum Biotechnologies
|
$4.74 | $30.00 | $98.6M | -- | $0.00 | 0% | -- |
|
CAPR
Capricor Therapeutics
|
$14.01 | -- | $637M | -- | $0.00 | 0% | 19.15x |
|
EYPT
EyePoint Pharmaceuticals
|
$7.33 | $33.45 | $500.3M | -- | $0.00 | 0% | 8.13x |
|
RGNX
Regenxbio
|
$7.40 | $37.64 | $366.6M | -- | $0.00 | 0% | 4.19x |
|
SAVA
Cassava Sciences
|
$2.34 | -- | $112.6M | -- | $0.00 | 0% | 2.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TECX
Tectonic Therapeutic
|
-- | 0.436 | -- | -- |
|
ADVM
Adverum Biotechnologies
|
-- | 3.113 | -- | 5.54x |
|
CAPR
Capricor Therapeutics
|
-- | 1.768 | -- | 4.17x |
|
EYPT
EyePoint Pharmaceuticals
|
-- | 2.791 | -- | 5.21x |
|
RGNX
Regenxbio
|
-- | 4.247 | -- | 2.73x |
|
SAVA
Cassava Sciences
|
-- | -5.281 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic
|
-- | -$19.6M | -- | -- | -- | -$42.4M |
|
ADVM
Adverum Biotechnologies
|
-- | -$29.2M | -69.14% | -69.14% | -2922.1% | -$21.3M |
|
CAPR
Capricor Therapeutics
|
-- | -$13M | -143.31% | -143.31% | -575.24% | -$11.7M |
|
EYPT
EyePoint Pharmaceuticals
|
$9.8M | -$32.7M | -50.67% | -50.67% | -278.99% | -$40.6M |
|
RGNX
Regenxbio
|
$11.8M | -$62.1M | -69.62% | -69.62% | -242.91% | -$40.9M |
|
SAVA
Cassava Sciences
|
-- | -$30.6M | -- | -- | -- | -$18.3M |
Tectonic Therapeutic vs. Competitors
-
Which has Higher Returns TECX or ADVM?
Adverum Biotechnologies has a net margin of -- compared to Tectonic Therapeutic's net margin of -2713.4%. Tectonic Therapeutic's return on equity of -- beat Adverum Biotechnologies's return on equity of -69.14%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic-- -$1.20 -- ADVMAdverum Biotechnologies-- -$1.30 $144.1M -
What do Analysts Say About TECX or ADVM?
Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 47.68%. On the other hand Adverum Biotechnologies has an analysts' consensus of $30.00 which suggests that it could grow by 526.88%. Given that Adverum Biotechnologies has higher upside potential than Tectonic Therapeutic, analysts believe Adverum Biotechnologies is more attractive than Tectonic Therapeutic.
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic3 0 0 ADVMAdverum Biotechnologies6 1 0 -
Is TECX or ADVM More Risky?
Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison Adverum Biotechnologies has a beta of 0.912, suggesting its less volatile than the S&P 500 by 8.787%.
-
Which is a Better Dividend Stock TECX or ADVM?
Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adverum Biotechnologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Adverum Biotechnologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or ADVM?
Tectonic Therapeutic quarterly revenues are --, which are smaller than Adverum Biotechnologies quarterly revenues of $1M. Tectonic Therapeutic's net income of -$17.7M is higher than Adverum Biotechnologies's net income of -$27.1M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Adverum Biotechnologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus -- for Adverum Biotechnologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic-- -- -- -$17.7M ADVMAdverum Biotechnologies-- -- $1M -$27.1M
-
Which has Higher Returns TECX or CAPR?
Capricor Therapeutics has a net margin of -- compared to Tectonic Therapeutic's net margin of -555.2%. Tectonic Therapeutic's return on equity of -- beat Capricor Therapeutics's return on equity of -143.31%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic-- -$1.20 -- CAPRCapricor Therapeutics-- -$0.38 $68.3M -
What do Analysts Say About TECX or CAPR?
Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 47.68%. On the other hand Capricor Therapeutics has an analysts' consensus of -- which suggests that it could grow by 194.69%. Given that Capricor Therapeutics has higher upside potential than Tectonic Therapeutic, analysts believe Capricor Therapeutics is more attractive than Tectonic Therapeutic.
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic3 0 0 CAPRCapricor Therapeutics0 0 0 -
Is TECX or CAPR More Risky?
Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison Capricor Therapeutics has a beta of 3.980, suggesting its more volatile than the S&P 500 by 298.019%.
-
Which is a Better Dividend Stock TECX or CAPR?
Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Capricor Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or CAPR?
Tectonic Therapeutic quarterly revenues are --, which are smaller than Capricor Therapeutics quarterly revenues of $2.3M. Tectonic Therapeutic's net income of -$17.7M is lower than Capricor Therapeutics's net income of -$12.6M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Capricor Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 19.15x for Capricor Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic-- -- -- -$17.7M CAPRCapricor Therapeutics19.15x -- $2.3M -$12.6M
-
Which has Higher Returns TECX or EYPT?
EyePoint Pharmaceuticals has a net margin of -- compared to Tectonic Therapeutic's net margin of -278.99%. Tectonic Therapeutic's return on equity of -- beat EyePoint Pharmaceuticals's return on equity of -50.67%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic-- -$1.20 -- EYPTEyePoint Pharmaceuticals93.01% -$0.54 $218.7M -
What do Analysts Say About TECX or EYPT?
Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 47.68%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.45 which suggests that it could grow by 356.41%. Given that EyePoint Pharmaceuticals has higher upside potential than Tectonic Therapeutic, analysts believe EyePoint Pharmaceuticals is more attractive than Tectonic Therapeutic.
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic3 0 0 EYPTEyePoint Pharmaceuticals8 0 0 -
Is TECX or EYPT More Risky?
Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.455, suggesting its more volatile than the S&P 500 by 45.456%.
-
Which is a Better Dividend Stock TECX or EYPT?
Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or EYPT?
Tectonic Therapeutic quarterly revenues are --, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $10.5M. Tectonic Therapeutic's net income of -$17.7M is higher than EyePoint Pharmaceuticals's net income of -$29.4M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 8.13x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic-- -- -- -$17.7M EYPTEyePoint Pharmaceuticals8.13x -- $10.5M -$29.4M
-
Which has Higher Returns TECX or RGNX?
Regenxbio has a net margin of -- compared to Tectonic Therapeutic's net margin of -246.3%. Tectonic Therapeutic's return on equity of -- beat Regenxbio's return on equity of -69.62%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic-- -$1.20 -- RGNXRegenxbio48.81% -$1.17 $301.4M -
What do Analysts Say About TECX or RGNX?
Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 47.68%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 408.6%. Given that Regenxbio has higher upside potential than Tectonic Therapeutic, analysts believe Regenxbio is more attractive than Tectonic Therapeutic.
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic3 0 0 RGNXRegenxbio6 0 0 -
Is TECX or RGNX More Risky?
Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.
-
Which is a Better Dividend Stock TECX or RGNX?
Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or RGNX?
Tectonic Therapeutic quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $24.2M. Tectonic Therapeutic's net income of -$17.7M is higher than Regenxbio's net income of -$59.6M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 4.19x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic-- -- -- -$17.7M RGNXRegenxbio4.19x -- $24.2M -$59.6M
-
Which has Higher Returns TECX or SAVA?
Cassava Sciences has a net margin of -- compared to Tectonic Therapeutic's net margin of --. Tectonic Therapeutic's return on equity of -- beat Cassava Sciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic-- -$1.20 -- SAVACassava Sciences-- -$0.58 -- -
What do Analysts Say About TECX or SAVA?
Tectonic Therapeutic has a consensus price target of $74.67, signalling upside risk potential of 47.68%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4857.27%. Given that Cassava Sciences has higher upside potential than Tectonic Therapeutic, analysts believe Cassava Sciences is more attractive than Tectonic Therapeutic.
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic3 0 0 SAVACassava Sciences0 0 0 -
Is TECX or SAVA More Risky?
Tectonic Therapeutic has a beta of 1.194, which suggesting that the stock is 19.37% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.
-
Which is a Better Dividend Stock TECX or SAVA?
Tectonic Therapeutic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or SAVA?
Tectonic Therapeutic quarterly revenues are --, which are smaller than Cassava Sciences quarterly revenues of --. Tectonic Therapeutic's net income of -$17.7M is higher than Cassava Sciences's net income of -$27.9M. Notably, Tectonic Therapeutic's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic is -- versus 2.57x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic-- -- -- -$17.7M SAVACassava Sciences2.57x -- -- -$27.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
